Atley Solutions and Perceptive Discovery Announce Collaboration
Atley Solutions and Perceptive Discovery have formed a significant strategic alliance to enhance the development of astatine-211 (At-211) radiopharmaceuticals. This partnership commences with the sale of two cutting-edge Atley C100 modules, heralding a new chapter in their quest for targeted alpha therapy advancements. This collaboration signifies a major stride for both companies in the field of medical innovation.
Strategic Developments in Radiopharmaceuticals
One of the Atley C100 modules will find its home at Perceptive Discovery's laboratory, marking history as the first installation in a commercial Contract Research Organization (CRO) setting within the United States. The second module will be set up in partnership with Queen Mary University of London, marking a groundbreaking development for At-211 capabilities in the United Kingdom.
Expanding Access to Astatine-211
This collaboration is more than just a business agreement; it's a commitment to expanding the horizons of radiopharmaceutical development. By capitalizing on their respective strengths, Atley and Perceptive aim to foster innovations that will potentially change patient outcomes in oncology. The shared vision is to leverage advanced systems, technical know-how, and specialized services for cultivating next-generation treatments.
Features of the Atley C100 Module
The Atley C100 stands as the only automated manufacturing unit dedicated to Ast-211 radiopharmaceuticals, ensuring consistent production quality, scalability, and operator safety. The establishment of these systems in the US and UK not only enhances local infrastructures but also offers clients immediate access to world-class resources.
Advancing Precision Oncology with At-211
The installation of these modules will bolster several capabilities:
- Facilitation of standardized production processes for At-211 radiopharmaceuticals.
- Foundation for discovery, preclinical evaluations, and practical drug development.
- Platforms that can scale from early research phases to full clinical manufacturing.
- Launch of dedicated At-211 capabilities in commercial CRO environments across both regions.
The ultimate goal of Atley and Perceptive is to establish a multi-tier partnership encompassing equipment sharing, service provisions, and knowledge transfer. Together, they aspire to advance the radiopharmaceutical field, facilitating rapid exploration and validation of innovative therapies harnessing At-211. This strategic alignment is pivotal as researchers look toward the future of targeted cancer treatments.
Expert Insights on the Partnership
Ben Murphy, the CEO of Perceptive Discovery, expressed enthusiasm regarding the collaboration: "At-211 is one of the most promising radionuclides for targeted radionuclide therapy, and Atley is at the forefront of At-211 innovation. Through our partnership, the combination of Atley's technology and our world-leading capabilities will accelerate the development of the next generation of radiopharmaceutical products."
Milton Lönnroth, CEO of Atley Solutions, remarked, "This partnership represents a major milestone for the global At-211 ecosystem. By equipping Perceptive Discovery with our Atley C100 technology, we enable our shared customers to develop At-211-based radiopharmaceuticals faster and more efficiently. Together, we are shaping the landscape of oncology treatment for years to come.”
About Atley Solutions
Atley Solutions prides itself on being a leader in the commercial development and manufacturing of At-211 radiopharmaceuticals. The Atley C100 module is a pioneering technology that addresses vital challenges in the production and scalability of radionuclides. Alongside technological innovations, Atley also offers comprehensive radiopharmaceutical development services, ensuring quality and efficiency.
About Perceptive Discovery
Perceptive Discovery specializes in bridging scientific innovation with clinical reality through advanced preclinical and translational solutions. Their expertise spans across various research domains, including radiochemistry and oncology, allowing them to provide integrated workflows that yield high-quality, actionable insights for their partners, which include various biotech and pharmaceutical entities worldwide.
Frequently Asked Questions
What is the primary purpose of the collaboration between Atley and Perceptive?
The collaboration aims to enhance the development and manufacturing capabilities of astatine-211 (At-211) radiopharmaceuticals, facilitating advancements in targeted alpha therapy.
Where will the Atley C100 modules be installed?
One module will be installed at Perceptive Discovery's laboratory in the US, while the second will be housed at Queen Mary University of London in the UK.
What are the advantages of using the Atley C100?
The Atley C100 offers standardized manufacturing, scalability, operator safety, and a powerful platform for drug development in oncology.
How does this partnership impact the field of oncology?
This partnership is expected to accelerate the discovery and development of targeted cancer therapies, establishing robust infrastructure for At-211 radiopharmaceuticals.
Who are the key executives involved in this collaboration?
Ben Murphy, CEO of Perceptive Discovery, and Milton Lönnroth, CEO of Atley Solutions, are the main executives driving this partnership forward.
